Vimarsana
Biggest News Aggregation in the World

Page 16 - Pfizer Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pfizer Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pfizer Ventures Today - Breaking & Trending Today

ImCheck fetches €96M for antibodies that activate immune cells against cancer - Vimarsana News

ImCheck fetches €96M for antibodies that activate immune cells against cancer

ImCheck Therapeutics aims to broaden the reach of cancer immunotherapy with antibody drugs that activate a rare but powerful type of immune cell called gamma delta T cells. The biotech has unveiled €96 million to advance its pipeline, including a lead candidate in development for both liquid and solid tumors.

Anjarium Biosciences appoints Stephen Yoo, MD as Chief Executive Officer - Vimarsana News

Anjarium Biosciences appoints Stephen Yoo, MD as Chief Executive Officer

/PRNewswire/ -- Anjarium Biosciences AG ("Anjarium"), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today...

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) - Vimarsana News

ImCheck Closes Upsized EUR 96 Million (USD 103 Million)

Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C...

ImmunOs Therapeutics Raises $74M in Series B Financing - Vimarsana News

ImmunOs Therapeutics Raises $74M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference - Vimarsana News

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com